Quest Diagnostics announced two advancements in its Quest AD-Detect® blood tests for Alzheimer's disease. The company will add the FDA-cleared Elecsys® pTau217 test, the first single-assay blood test for amyloid pathology, to its portfolio by late 2026. Additionally, Quest is launching a new multi-biomarker AD-Detect test combining pTau217, amyloid beta 42/40, and APOE genetic risk markers, achieving a low 10% indeterminate rate. These tests offer less invasive, cost-effective alternatives to PET scans and cerebrospinal fluid testing, improving access and accuracy for Alzheimer's diagnosis nationwide.
Quest Diagnostics announced that CEO Jim Davis will present the company's strategy, performance, and insights on market trends at the Baird 2026 Global Healthcare Conference in New York on September 15, 2026. The session will include a fireside chat ...
Humanity Health Inc. and Quest Diagnostics have launched the Humanity Biological Age test in the U.S. through Quest's consumer platform questhealth.com. For $29, individuals can add this test to select health profiles without extra blood draws, recei...
Digi Power X Inc insiders, including President Amar Alec and CEO Michel Amar, purchased shares in recent open-market transactions. Alec bought 10,000 shares at an average price of $3.86, while Amar acquired 20,000 shares at $3.60 each. These purchase...
Quest Diagnostics announced that Sam Samad, the company's Executive Vice President and CFO, will present on the company's strategy, performance, and market trends at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September...
